Clinical Trials
10 trialsNCT05329766 2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT04736173 2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT05676931 2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT04791839 2026-05-06
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT07134556 2026-05-01
ADJUNCT
MedSIR
Phase 2 Withdrawn
NCT05130177 2026-03-31
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting